*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title, registration ...
Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical ...
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) has acquired VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics, the company announced Thursday. The micro-cap ...
Hosted on MSN
Cadrenal Therapeutics acquires VLX-1005 from Veralox
An announcement from Cadrenal Therapeutics, Inc. ( (CVKD)) is now available. On December 10, 2025, Cadrenal Therapeutics acquired VLX-1005 and related assets from Veralox Therapeutics, enhancing its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback